Bei Akademie registrieren
Kymera Therapeutics stock, KYMR

Kymera Therapeutics stock advances KT-579 after positive Phase 1 data

Published on 10/30/2026 at 03:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Kymera Therapeutics stock advances its immunology pipeline with positive early data for oral drug candidate KT-579. The company also outlined upcoming clinical milestones.

Kymeras Pipeline und Quartalszahlen

  • KT-579 zeigte in einer Phase-1-Studie bei gesunden Freiwilligen eine tiefe und anhaltende IRF5-Degradation.
  • Die KT-621-Studie BROADEN2 soll noch 2026 erste Ergebnisse zur atopischen Dermatitis liefern.
  • Kymera verfügte Ende September über 1,6 Milliarden US-Dollar an liquiden Mitteln und Anlagen.
Kymera Therapeutics stock, KYMR, KT-579, IRF5, Phase 1, Quartalszahlen, Illustration mit AI erstellt.
Kymera Therapeutics stock, KYMR, KT-579, IRF5, Phase 1, Quartalszahlen, Illustration mit AI erstellt.

Kymera Therapeutics reported positive Phase 1 results for its oral IRF5 degrader KT-579 alongside third-quarter financial results on October 29, 2026. The company said the findings support further development in autoimmune diseases, while the financial update showed sharply higher research spending and a wider net loss.

According to the Kymera 8-K filing, KT-579 produced median IRF5 degradation of at least 90% across multiple dose levels in the multiple-ascending-dose portion of the trial. The company also reported inhibition of several disease-relevant biomarkers, including TNF alpha, IL-12/23p40, IL-1 beta and IFN beta. Kymera said no serious or severe adverse events occurred and that no adverse events led to discontinuation.

Clinical milestones remain central

Kymera plans to start the KT-579 LUMORA Phase 1b study in patients with lupus by early 2027. The company said the study is designed to assess biological activity and safety over 16 weeks in approximately 30 adults with systemic lupus erythematosus.

For KT-621, the last patient completed the week 16 visit in the BROADEN2 Phase 2b trial in moderate to severe atopic dermatitis during October. Kymera expects to report topline data by year-end 2026 and, subject to regulatory discussions, plans to start its first Phase 3 atopic dermatitis study by mid-2027. Enrollment in the BREADTH Phase 2b asthma trial is continuing, with topline data expected in late 2027.

Higher investment, extended runway

Kymera reported no collaboration revenue for the third quarter, compared with 2.8 million US dollars a year earlier. Research and development expense rose to 128.5 million US dollars from 74.1 million US dollars, including 10.9 million US dollars in stock-based compensation. Net loss widened to 132.0 million US dollars from 82.2 million US dollars.

As of September 30, Kymera held 1.6 billion US dollars in cash, cash equivalents and investments. Management said this balance should fund operations into 2029, covering several clinical milestones. For investors, the update leaves the valuation discussion focused on clinical execution and the timing of data readouts rather than near-term collaboration revenue.

Kymera Therapeutics: key facts

  • Company: Kymera Therapeutics, Inc.
  • Ticker: KYMR
  • Exchange: Nasdaq
  • Reporting period: Third quarter ended September 30, 2026
  • Net loss: 132.0 million US dollars
  • Cash, cash equivalents and investments: 1.6 billion US dollars as of September 30, 2026

The broader US biotechnology market remains sensitive to clinical data, financing conditions and regulatory milestones; see Current market reports.

More company news and analysis can be found on the Kymera Therapeutics stock topic page.

Disclaimer...
en | boerse | 70432295 |